$CNXC

Concentrix Corp 2026: Revenue $2.45B, EPS ($16.24) — 10-Q Summary

Concentrix Corp reported Q2 2026 revenue of $2.45B, down 1.2% YoY, and a net loss of $988.11M, versus prior-year income of $88.11M. Growth in banking and retail was offset by declines in tech and healthcare. The company is focusing on cost reduction and AI-driven services.

Original reporting
Published Oct 7, 2026, 12:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 12:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Concentrix Corp 2026: Revenue $2.45B, EPS ($16.24) — 10-Q Summary — source image
Decision brief

The 30-second read

$CNXCBearishLow
01

Why it matters

The loss may trigger short‑term selling, but cost‑reduction plans could mitigate longer‑term concerns.

02

Market read

Earnings recap with negative surprise; limited trading action.

03

What to watch

Potential upside from GenAI service expansion and upcoming Q4 seasonality.

Relevance 4/10Novelty 2/10Timing: post‑release recap

Background

Concentrix filed its 10‑Q for Q3 2026, reporting a slight revenue decline and a sizable net loss.

Company-level read

Ticker impact

$CNXCBearishHigh confidence
Context

The article recaps Concentrix Corp's 10‑Q results showing a $988M net loss and $16.24 EPS, which were already public on Sep 29 2026.

Expected impact

downward pressure as investors price the unexpected loss

Evidence & confidence

Losses and negative EPS are already known; no new catalyst, but the magnitude may keep the stock under pressure.

Market effects

Highlights weakness in the BPO sector, especially for firms with high foreign‑exchange exposure.

Limited to U.S. and European investors tracking outsourcing stocks.

Minimal; no broader macro or geopolitical link.

Counterpoint

If the loss is already priced, the stock could stabilize on cost‑cutting initiatives.

Key entities

  • Concentrix Corp

    U.S. business process outsourcing firm (ticker CNXC).

Related articles

$CNXCHighAI 8/10

Concentrix earnings analysis: questions answered and next catalysts

Concentrix Corp (CNXC) reported Q3 earnings with a $0.21 EPS beat ($2.92) but a $30M revenue miss ($2.45B vs. $2.48B est). Shares initially dropped 9.77% before recovering 3.12%. Management highlighted AI-driven revenue growth (50% of total) and cash flow strength ($218M), but revenue declines due to specific client exits and offshoring. The dividend was raised to $0.37/share. Growth is expected to return in 2028, with key catalysts including Q4 earnings and debt paydown milestones.

$CNXCMedAI 8/10

Why Concentrix Stock Ended Up Moving Higher Today

Concentrix (CNXC) reported fiscal Q3 revenue below estimates due to client shifts, but earnings beat expectations. CEO Christopher Caldwell attributed the shortfall to client preferences, not customer loss. The stock initially dropped but recovered, up 3% by midday. Analysts' average price target is $33.50, over 30% above current levels.

$LQDAMed

Stocks making the biggest moves midday: Rogers, United Therapeutics, Moderna, FormFactor & more

Rogers rose 10% on higher earnings guidance ($3.80 vs. $3.65 consensus). Liquidia fell 25% after a patent infringement ruling, while United Therapeutics gained 15%. Jabil dropped 7% despite beating earnings and revenue estimates. Concentrix climbed 5% on strong earnings but issued weak guidance. Moderna fell 7% after a Citi downgrade. FormFactor gained 8% on a Deutsche Bank buy rating. Cal-Maine Foods declined 2% on a wider-than-expected loss.

$CNXCLow

Why Concentrix (CNXC) Stock Is Up Today

Concentrix (CNXC) stock rose 4% after reporting a Q3 net loss of $988.1M, driven by a $1.5B goodwill impairment charge. Revenue fell 1.2% YoY to $2.45B, missing estimates. Adjusted EPS was $2.92. The company cited AI deployments and client decisions for the decline. Shares later cooled to $25.73, up 1%.